Mechanism of Action: Organic Anion Transporting Polypeptide 2B1 Inhibitors

Drugs with Mechanism of Action: Organic Anion Transporting Polypeptide 2B1 Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-001	Oct 17, 2023		DISCN	Yes	No			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-002	Oct 17, 2023		RX	Yes	No
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-001	Oct 17, 2023		DISCN	Yes	No
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-003	Oct 17, 2023		RX	Yes	Yes

Market dynamics and patent landscape for OATP2B1 inhibitors

Last updated: April 25, 2026

What is the target and which drugs sit in the OATP2B1 inhibitor landscape?

Organic Anion Transporting Polypeptide 2B1 (OATP2B1; SLC21A9) is a membrane transporter that moves a range of endogenous substrates and xenobiotics, including multiple orally dosed drugs. Inhibiting OATP2B1 is used to change drug exposure and, in cancer and inflammatory indications, can also modulate intracellular availability of transporter-dependent agents.

Across the market, “OATP2B1 inhibitor” is not a single class of commercially established medicines with one dominant active ingredient. Instead, the practical landscape is defined by:

• Drug-drug interaction (DDI) inhibition: Many marketed molecules inhibit OATP family transporters, including OATP2B1, at clinically relevant exposures.
• Development programs aimed at transporter-mediated pharmacology: A smaller set of molecules are designed or optimized specifically to inhibit OATP2B1 (or to achieve selectivity within the OATP family).

Because OATP family inhibition often co-occurs with inhibition of other OATP transporters (notably OATP1B1/1B3, OATP2B1, and OATP1A2), product differentiation depends on selectivity, unbound potency at relevant concentrations, and clinical DDI risk.

Which market dynamics matter for OATP2B1 inhibitors?

1) Commercial value is tied to DDI positioning

For OATP2B1 inhibitors, the fastest path to revenue typically follows one of two models:

• Adjunct / booster strategy: A transporter inhibitor is developed or used to increase exposure of a co-administered drug, lowering dose or improving efficacy. This model ties value to the partner drug’s uptake.
• Standalone targeted therapy: The transporter inhibitor is the active pharmacology driver in an indication where transporter-mediated substrate uptake matters (often oncology).

In both models, commercial adoption is constrained by the same economic and regulatory drivers:

• Labeling and risk management around DDIs
• Need for therapeutic drug monitoring (TDM) or dose adjustment guidance for co-administered CYP and transporter substrates
• Prescriber adoption in specialties that already manage complex polypharmacy

2) Selectivity is a sales lever

OATP inhibition is linked to transporter network effects. Programs that inhibit OATP2B1 without also strongly inhibiting other OATP transporters generally face:

• fewer clinically significant transporter-related DDIs
• less requirement for broad dose adjustment labeling

Companies therefore compete on unbound IC50/Ki versus plasma protein binding, plus time-dependent inhibition where relevant, and on in vitro-to-in vivo translation of inhibitory potency.

3) Development cost centers: DDI clinical packages

Even for “targeted” OATP2B1 inhibitors, sponsors typically must deliver:

• clinical DDI studies with sensitive OATP substrates
• in vitro transporter panels and mechanistic models
• PBPK simulations that translate in vitro transporter inhibition into expected clinical exposure changes

This shifts economics toward molecules with a clear therapeutic window and manageable DDI liabilities.

4) Patent value depends on whether OATP2B1 inhibition is central to claims

Patent strength often correlates with claim structure:

• Claims covering “OATP2B1 inhibition” as a defined pharmacological effect can be broader, but they face prior art risk from known transporter inhibitors.
• Composition-of-matter claims tied to specific chemical scaffolds can be stronger if the scaffold is novel and non-obvious over earlier OATP inhibitors.
• Method-of-treatment claims can provide additional layers, but only if tied to a specific clinical phenotype or therapeutic use with supporting data.

What does the patent landscape look like in practice?

A full, molecule-by-molecule global map requires a dataset with structured claims, assignee ownership, priority dates, and family linkages. The following is a practical view of how the landscape usually clusters for OATP2B1 inhibitors:

Cluster A: Broad OATP inhibitors that include OATP2B1

These patents often cover analogs of known transporter inhibitors where OATP2B1 is one of several inhibited transporters. They can remain active through multiple continuations, particularly where claim sets cover:

• substitution patterns on a core scaffold
• polymorph or salt forms
• specific dosing regimens to achieve transporter inhibition

Market implication: new entrants face the highest risk of obviousness and anticipation if they are only optimizing potency without a new scaffold or new selectivity profile.

Cluster B: “Selective OATP2B1” optimization

These programs emphasize selectivity within the OATP family:

• in vitro transporter panels across OATP1B1, OATP1B3, OATP2B1, and sometimes OATP1A2
• unbound potency targets that reduce off-target transporter effects
• PBPK-driven dosing guidance

Market implication: selectivity patents can be enforceable even when the therapeutic indication is broad, if claims are tied to measurable inhibition parameters.

Cluster C: Conjugates and prodrugs aimed at transporter-mediated uptake

Some transporter-linked strategies use OATP transport to deliver drugs into tissues. This can invert the inhibitory strategy, but the patent landscape frequently overlaps because:

• prodrug activation and uptake can involve OATP2B1
• compounds can be engineered to reduce transporter off-target interactions

Market implication: even when the program is not “OATP2B1 inhibitor” by marketing language, the patent claims may still encompass OATP2B1 inhibition as part of the mechanistic package.

Cluster D: Use-based patents that target transporter-related disease pathways

These include method-of-treatment claims for cancers or inflammatory conditions where transporter substrates and transporter expression are implicated. Even if OATP2B1 is not the only transporter involved, patents often claim:

• treatment regimens with a transporter inhibitor
• biomarker-defined patient subsets (e.g., transporter expression levels)
• combination regimens with transporter substrate drugs

Market implication: enforcement can be strong if the claims specify the transporter mechanism and the clinical biomarker linkage.

Who holds the most relevant rights and what are the common claim patterns?

Without a defined list of specific molecules and their patent families, it is not possible to responsibly enumerate assignees, priority dates, expiry dates, and remaining exclusivity for OATP2B1 inhibitors worldwide. The OATP2B1 inhibitor space is also highly fragmented across chemical series and therapeutic use patents, and the same chemical may be claimed in multiple jurisdictions under different family members.

What can be stated at a claims level (and used for freedom-to-operate and licensing strategy) is the recurring pattern of how OATP2B1 inhibition is claimed:

Composition-of-matter patterns

• Generic formula claims with defined substituent scope, where potency and IC50 parameters are often embedded as examples rather than limiting language.
• Preferred embodiments with specific ring systems and substitution patterns, plus salt/polymorph coverage.
• Prodrug variants where OATP2B1-related exposure is a stated rationale (even if the mechanism is delivery rather than inhibition).

Method-of-treatment patterns

• “Treating” language for an indication plus a mechanism statement referencing OATP2B1 inhibition.
• Combination therapy claims with co-administered substrate drugs where OATP2B1 inhibition changes exposure or increases therapeutic index.
• Patient selection claims tied to transporter expression or genotype.

Method-of-inhibition / DDI patterns

• Claims that cover increasing systemic exposure of a co-administered drug via OATP2B1 inhibition.
• Claims that define dose scheduling for maximal inhibition while managing toxicity.

How should businesses model market entry using the patent-dynamics interplay?

1) Decide whether you are defending against DDI or building a therapeutic differentiation

• DDI booster model: Expect to encounter earlier OATP inhibitor patents, including those where OATP2B1 is one of many inhibited transporters.
• Standalone inhibitor model: Expect to face overlap from transporter biology patents and oncology method claims, not only chemistry patents.

2) Use claim-scope screening tied to measurable potency

In negotiations and FTO triage, potency is often the bridge between scientific relevance and legal relevance. For OATP2B1, look for:

• reported unbound inhibitory potency (IC50 or Ki)
• transporter-selectivity matrices
• PBPK or clinical DDI data tied to OATP2B1 inhibition

3) Prioritize freedom-to-operate around the exact chemical scaffold

For OATP2B1 inhibitors, scaffold-level similarity is the highest-probability driver of infringement risk. If a new program does not share core scaffolds with earlier families, it shifts risk away from direct anticipation toward obviousness based on SAR teachings.

4) Plan around last-expiring family members, not just the primary compound

OATP inhibitor families commonly contain:

• continuation applications
• divisionals
• salt/polymorph patents
• method claims in separate families

Licensing and entry timing depend on the longest-tail elements.

What is the actionable bottom line for R&D and licensing?

A robust OATP2B1 inhibitor strategy should treat the patent landscape as two-layer risk:

1. Chemistry layer: composition-of-matter claims on chemical scaffolds plus salt/polymorph continuations.
2. Mechanism and method layer: method-of-treatment or exposure-modulation claims where OATP2B1 inhibition is tied to defined outcomes, dosing, or combinations.

Commercially, the value proposition hinges on minimizing clinically meaningful off-target transporter inhibition and staying within DDI risk tolerance. That drives both target product profile and the evidence package required by regulators and payers.

---

Key Takeaways

• OATP2B1 inhibitors are a niche category where DDI risk management is often as important as efficacy.
• The patent landscape typically clusters into broad OATP inhibitors, selectivity-focused series, and use-based (method) families tied to transporter biology or exposure modulation.
• Market success is driven by selectivity (unbound inhibitory potency and off-target inhibition) and by the sponsor’s ability to package clinical DDI data and PBPK support.
• Patent value depends on whether claims center on a novel scaffold and whether method claims tightly link OATP2B1 inhibition to defined therapeutic outcomes.

FAQs

1) Are there approved drugs that are marketed specifically as OATP2B1 inhibitors?

The market is dominated by compounds whose OATP2B1 inhibition is part of a broader transporter inhibition profile rather than single-asset “OATP2B1 inhibitor” branding.

2) Why does selectivity across OATP transporters drive development cost?

Because selectivity determines the breadth of clinically relevant DDIs and thus the size of the required clinical DDI package.

3) What claim types most often survive in transporter inhibitor litigation?

Composition-of-matter claims on chemical scaffolds and continuations, plus method claims that require specific transporter-mediated outcomes, tend to provide the strongest enforceable layers.

4) How do combination regimens affect patent risk and commercial strategy?

Combination claims often broaden enforceability but increase the evidence burden and the specificity needed in dosing and biomarker context.

5) What is the main economic advantage of an “OATP2B1 booster” approach?

It ties value to uptake of a partner substrate drug and can reduce dose or improve exposure, but it raises regulatory and labeling complexity around DDIs.

---

References

[1] Organisation for Economic Co-operation and Development (OECD). Guidance documents on transporter-mediated drug interactions and PBPK modeling principles. OECD Publishing.
[2] FDA. Guidance for Industry: Drug Interaction Studies. U.S. Food and Drug Administration.
[3] European Medicines Agency (EMA). Guideline on the investigation of drug interactions. European Medicines Agency.
[4] DrugBank. OATP2B1 (SLC21A9) target entry and interaction data.
[5] University of Washington. Drug transporter knowledge base (OATP2B1 entries) and related literature summaries.